Eravacycline: From broad-spectrum coverage to novel clinical applications

Eravacycline is a novel, fully synthetic fluorocycline antibiotic with broad-spectrum activity against Gram-positive, Gram-negative, aerobic, and anaerobic pathogens, including multidrug-resistant (MDR) strains. It maintains efficacy despite common tetracycline resistance mechanisms, such as efflux pumps and ribosomal protection proteins. Its pharmacokinetic profile is characterized by extensive tissue penetration, particularly into the epithelial lining fluid and alveolar macrophages. Eravacycline is particularly active against MDR pathogens such as carbapenem-resistant Enterobacterales and Acinetobacter baumannii. It also demonstrates efficacy against Achromobacter spp., Burkholderia cepacia complex, Stenotrophomonas maltophilia, and rapidly growing mycobacteria. Moreover, owing to its minimal disruption of the intestinal microbiota, it may help reduce the risk of Clostridioides difficile infection and could serve as an adjunctive therapeutic option in severe or fulminant cases. Phase III trials (IGNITE1 and IGNITE4) demonstrated noninferiority of eravacycline compared with carbapenems in complicated intra-abdominal infections (cIAIs), supporting its approval for this indication. It is generally well tolerated, with adverse effects mainly limited to mild gastrointestinal. Beyond its approved indication for cIAIs, eravacycline shows therapeutic potential in multiple clinical contexts, such as polymicrobial infections from skin and soft tissue (necrotizing fasciitis) or pelvic inflammatory disease, pulmonary and biliary tract infections, β-lactam allergy, infections in immunocompromised patients, C. difficile infection, and community-acquired sepsis of unknown source. Collectively, real-world evidence and its broad-spectrum antimicrobial activity support eravacycline as a promising therapeutic option with potential utility extending beyond its current indications.